Excellent. Did you read the article that Titan V posted?
Not publicly traded companies, but there are some examples of extreme multiples being paid for early stage biotechs in that article.
A buyout of ONCS is possible at some point, but it is pure conjecture at this point as you well know. Nothing along those lines will happen unless the P2b interim results (known only by Merck, ONCS, and few others) is positive.
We should see some positive results "sometime" in 2015.
News 
Market Data 
Discover 
